Valeant Drug Pricing

David Amsellem of Piper Jaffray was asked for his opinion on reports that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has yet to proceed with proposed price cuts for some of its drugs. Speaking as a guest on CNBC, Amsellem said the report "doesn't surprise me" for several reasons...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and its top management officials told a group of U.S. senators the company is open to slashing the price of some of its drugs. Valeant executives suggested a 30 percent discount on some of its drugs for hospitals. However, the cost for many life-...